Timing of nodal metastasis in patients with eyelid sebaceous carcinoma and implications for surveillance and survival

眼睑皮脂腺癌患者淋巴结转移的时间及其对监测和生存的影响

阅读:1

Abstract

BACKGROUND/AIMS: Sebaceous carcinoma (SC) is a rare cancer with periocular predilection. Studies focused on patterns and timing of nodal metastasis are scarce.Our aim is to report patterns of regional nodal metastasis in patients with eyelid SC, including results of sentinel lymph node biopsy (SLNB). METHODS: All consecutive patients with eyelid SC treated during 1999-2023 were retrospectively reviewed.All subjects had standard of care surgery for eyelid SC and regional lymph node evaluation using physical examination and ultrasonography (US) at baseline and during the surveillance period. 38 patients with negative findings on US had SLNB to rule out microscopic metastasis.The frequency and timing of lymph node metastasis, the SLNB positivity rate, management of nodal metastasis, overall and disease-specific survival were analysed. RESULTS: A total of 138 patients were included. 30 patients (22%) had lymph node metastasis: 15 patients were diagnosed at the time of initial diagnosis of eyelid SC; 18 patients developed nodal metastasis during the follow-up period, at a median of 12 months (range, 1-132). Of 38 patients, 5 (13%) had a positive SLNB. Management of nodal metastasis entailed surgical resection of the involved nodal basins in 27 patients; 20 had adjuvant radiotherapy and 7 had adjuvant concurrent chemoradiation. In patients with nodal metastasis, the 2-year and 5-year disease-specific survival rates were 87.5% and 75.4%, respectively. CONCLUSIONS: One-half of the patients with eyelid SC with nodal metastasis had negative findings at initial presentation but developed nodal metastasis during follow-up, highlighting the importance of continued lymph node surveillance.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。